Pancreatic Cancer Research

ResearcherThe Cancer Institute HospitalActive in the last 2 years

Tsuyoshi Takeda

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-0786-8166; OpenAlex author ID A5070620598, A5100563881, A5130120350. Sources: OpenAlex.

Their work

Papers
48 (first author 2, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
69
Papers, trials and grants by year

2015: 1 paper · 2016: none · 2017: none · 2018: 1 paper · 2019: 2 papers · 2020: 3 papers · 2021: 8 papers · 2022: 8 papers · 2023: 10 papers · 2024: 3 papers · 2025: 6 papers · 2026: 6 papers

Papers 48

  1. Endoscopic Retrograde Cholangiopancreatography-guided Biliary Drainage with Duckbill-type Anti-reflux Metal Stent versus Endoscopic Ultrasound-guided Hepaticog… Co-author DOI 10.1002/deo2.70154↗
  2. Relative Dose Intensity and Outcomes in Elderly Patients With Resectable Pancreatic Cancer Receiving Neoadjuvant Chemotherapy. Co-author DOI 10.1002/jhbp.70058↗
  3. Prognostic model for pancreatic cancer based on machine learning of routine slides and transcriptomic tumor analysis. Co-author DOI 10.1038/s41416-025-03308-7↗
  4. Changing treatment outcomes in metastatic and recurrent pancreatic cancer: a real-world comparison before and after the availability of nanoliposomal irinoteca… Co-author DOI 10.1093/jjco/hyaf194↗
  5. Gastrointestinal Bleeding after Particle Radiotherapy for Pancreatic Cancer. Co-author DOI 10.1159/000550483↗
  6. Patient-derived orthotopic xenograft models recapitulate the peritoneal dissemination of pancreatic cancer and delineate its transcriptional and regulatory pro… Co-author DOI 10.1186/s13046-026-03668-9↗
  7. Outcomes of multi-hole self-expandable metal stents versus fully covered self-expandable metal stents for malignant distal biliary obstruction in unresectable … Co-author DOI 10.1002/deo2.70014↗
  8. Impact of second-line combination chemotherapy on post-progression survival in metastatic and recurrent pancreatic cancer. Co-author DOI 10.1007/s10147-025-02796-0↗
  9. Clinical predictors of KRAS mutation detection in liquid biopsies for pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.pan.2025.06.013↗
  10. Impact of Statin Use on Survival in Patients With Unresectable Pancreatic cancer Receiving Gemcitabine Plus Nab-Paclitaxel: A Multicenter Retrospective Study. Co-author DOI 10.1097/mpa.0000000000002411↗
  11. Blood Group Antigen Expression in Blood and Tumor in Relation to Survival Outcomes in Resected Pancreatic Cancer, Overall and by Adjuvant Chemotherapy Regimens. Co-author DOI 10.1245/s10434-025-17289-7↗
  12. Efficacy of Anamorelin in Advanced Pancreatic Cancer Patients with a Poor Performance Status. Co-author DOI 10.2169/internalmedicine.3577-24↗
  13. Outcomes of 6-mm diameter fully covered self-expandable metal stents for preoperative biliary drainage in pancreatic cancer. First author DOI 10.1002/deo2.360↗
  14. Caveolin-1 expression is a predictor of survival and recurrence patterns in resected pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.pan.2024.10.001↗
  15. Bone loss over time and risk of osteoporosis in advanced pancreatic cancer. Co-author DOI 10.1093/jjco/hyae028↗
  16. Post-operative mortality and recurrence patterns in pancreatic cancer according to KRAS mutation and CDKN2A, p53, and SMAD4 expression. Co-author DOI 10.1002/cjp2.323↗
  17. The efficacy and safety of a duckbill-type anti-reflux metal stent as the initial metal stent for distal malignant biliary obstruction in unresectable pancreat… Co-author DOI 10.1002/deo2.205↗
  18. Outcomes of pancreatic cancer with liver oligometastasis. Co-author DOI 10.1002/jhbp.1184↗
  19. Long-term outcomes of duckbill-type anti-reflux metal stents versus conventional covered metal stents in reinterventions after covered biliary metal stent dysf… Co-author DOI 10.1007/s00464-022-09836-0↗
  20. Analysis of prognostic factors for borderline resectable pancreatic cancer after neoadjuvant chemotherapy: the importance of CA19-9 decrease in patients with e… Co-author DOI 10.1016/j.hpb.2022.09.012↗
  21. Prognostic impact of osteosarcopenia in patients with advanced pancreatic cancer receiving gemcitabine plus nab-paclitaxel. Co-author DOI 10.1016/j.pan.2023.02.002↗
  22. Outcomes of lung oligometastasis in pancreatic cancer. Co-author DOI 10.1093/jjco/hyad111↗
  23. Clinical Efficacy of Neoadjuvant Chemotherapy with Gemcitabine plus S-1 for Resectable Pancreatic Ductal Adenocarcinoma Compared with Upfront Surgery. Co-author DOI 10.1245/s10434-023-13534-z↗
  24. Impact of the Extent of Weight Loss before Administration on the Efficacy of Anamorelin in Advanced Pancreatic Cancer Patients with Cachexia. Co-author DOI 10.2169/internalmedicine.0730-22↗
  25. Treatment Outcomes and Prognostic Factors of Gemcitabine Plus Nab-Paclitaxel as Second-Line Chemotherapy after Modified FOLFIRINOX in Unresectable Pancreatic C… Co-author DOI 10.3390/cancers15020358↗
  26. Early-onset pancreatic cancer: Clinical characteristics and survival outcomes. Co-author DOI 10.1016/j.pan.2022.04.003↗
  27. Treatment outcomes of nanoliposomal irinotecan as second-line chemotherapy after gemcitabine and nab-paclitaxel in metastatic and recurrent pancreatic cancer. Co-author DOI 10.1093/jjco/hyac145↗
  28. KRAS variant allele frequency, but not mutation positivity, associates with survival of patients with pancreatic cancer. Co-author DOI 10.1111/cas.15398↗
  29. Removal of a biliary self-expandable metal stent using the zipline technique for pancreatic cancer with duodenal stricture. First author DOI 10.1111/den.14190↗
  30. Impact of the COVID-19 Pandemic on the Management and End-of-life Care of Unresectable Pancreatic Cancer. Co-author DOI 10.2169/internalmedicine.0492-22↗
  31. Multiple Gastric Metastases after Distal Pancreatectomy for Pancreatic Cancer. Co-author DOI 10.2169/internalmedicine.8848-21↗
  32. CA19-9 Reduction After 4 Months of Treatment Is a Prognostic Factor for Locally Advanced Pancreatic Cancer. Co-author DOI 10.21873/invivo.13024↗
  33. Molecular Features and Clinical Management of Hereditary Pancreatic Cancer Syndromes and Familial Pancreatic Cancer. Co-author DOI 10.3390/ijms23031205↗
  34. Risk factors for gemcitabine plus nab-paclitaxel-induced interstitial lung disease in pancreatic cancer patients. Co-author DOI 10.1007/s10147-020-01827-2↗
  35. The impact of cachexia and sarcopenia in elderly pancreatic cancer patients receiving palliative chemotherapy. Co-author DOI 10.1007/s10147-021-01912-0↗
  36. A case of necrotic enteritis during neoadjuvant chemotherapy with gemcitabine and S-1 for resectable pancreatic ductal adenocarcinoma. Co-author DOI 10.1007/s12328-021-01480-w↗
  37. Improved prognosis of pancreatic cancer patients with peritoneal metastasis. Co-author DOI 10.1016/j.pan.2021.03.006↗
  38. The impact of body composition on short-term outcomes of neoadjuvant chemotherapy with gemcitabine plus S-1 in patients with resectable pancreatic cancer. Co-author DOI 10.1093/jjco/hyaa247↗
  39. The prognostic impact of tumour location and first-line chemotherapy regimen in locally advanced pancreatic cancer. Co-author DOI 10.1093/jjco/hyab014↗
  40. Treatment outcomes of erlotinib plus gemcitabine as late-line chemotherapy in unresectable pancreatic cancer. Co-author DOI 10.1093/jjco/hyab091↗
  41. Comparison of Treatment Outcomes Between Gemcitabine With Nab-Paclitaxel and Modified FOLFIRINOX for First-Line Chemotherapy in Metastatic and Recurrent Pancre… Co-author DOI 10.1097/mpa.0000000000001801↗
  42. Comprehensive comparison of clinicopathological characteristics, treatment, and prognosis of borderline resectable pancreatic cancer according to tumor locatio… Co-author DOI 10.1016/j.pan.2020.07.004↗
  43. Novel risk factors for recurrent biliary obstruction and pancreatitis after metallic stent placement in pancreatic cancer. Co-author DOI 10.1055/a-1244-1989↗
  44. Modified FOLFIRINOX as a second-line therapy following gemcitabine plus nab-paclitaxel therapy in metastatic pancreatic cancer. Co-author DOI 10.1186/s12885-020-06945-8↗
  45. A phase II trial of gemcitabine, S-1 and LV combination (GSL) therapy in patients with advanced pancreatic cancer. Co-author DOI 10.1007/s10637-018-0691-9↗
  46. Diagnostic yield of the plasma free amino acid index for pancreatic cancer in patients with diabetes mellitus. Co-author DOI 10.1016/j.pan.2019.07.002↗
  47. A Multicenter Open-Label Randomized Controlled Trial of Pancreatic Enzyme Replacement Therapy in Unresectable Pancreatic Cancer. Co-author DOI 10.1097/mpa.0000000000001079↗
  48. [IPMN and pancreatic cyst as high risk of pancreatic cancer]. Co-author DOI 10.11405/nisshoshi.112.1474↗

Closest collaborators

The 25 strongest of 69 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Naoki Sasahira · 44 shared papers, 2015–2026 · strength 7.39
  2. Takashi Sasaki · 39 shared papers, 2019–2026 · strength 6.54
  3. Masato Ozaka · 38 shared papers, 2020–2026 · strength 6.47
  4. Takafumi Mie · 34 shared papers, 2020–2026 · strength 5.81
  5. Takaaki Furukawa · 33 shared papers, 2020–2026 · strength 5.60
  6. Takeshi Okamoto · 26 shared papers, 2021–2026 · strength 4.88
  7. Akiyoshi Kasuga · 27 shared papers, 2020–2025 · strength 3.97
  8. Masato Matsuyama · 23 shared papers, 2020–2023 · strength 3.18
  9. Yu Takahashi · 14 shared papers, 2020–2026 · strength 2.22
  10. Yuto Yamada · 16 shared papers, 2020–2023 · strength 2.14
  11. Yosuke Inoue · 10 shared papers, 2020–2026 · strength 1.66
  12. Manabu Takamatsu · 8 shared papers, 2021–2026 · strength 1.26
  13. Hiroki Nakagawa · 7 shared papers, 2022–2025 · strength 1.25
  14. Tsuyoshi Hamada · 9 shared papers, 2015–2026 · strength 1.11
  15. Yousuke Nakai · 9 shared papers, 2015–2026 · strength 1.06
  16. Yukari Suzuki · 4 shared papers, 2025–2026 · strength 1.01
  17. Mitsuhiro Fujishiro · 5 shared papers, 2022–2026 · strength 0.83
  18. Tatsunori Suzuki · 5 shared papers, 2022–2026 · strength 0.79
  19. Atsushi Oba · 5 shared papers, 2023–2024 · strength 0.78
  20. Kiyoshi Hasegawa · 4 shared papers, 2022–2026 · strength 0.63
  21. Minoru Kitago · 4 shared papers, 2022–2026 · strength 0.63
  22. Yohei Masugi · 4 shared papers, 2022–2026 · strength 0.63
  23. Sho Uemura · 4 shared papers, 2022–2026 · strength 0.63
  24. Yoshihiro Ono · 4 shared papers, 2021–2024 · strength 0.60
  25. Jun Hamada · 2 shared papers, 2026 · strength 0.53

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.